Trial · NCT02728752
Results by group89
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 89
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) | Placebo | 21 | Participants | ||
| Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) | Octagam10% | 37 | Participants | ||
| Proportion of TIS Responders by Improvement Category at Week 16 | Placebo | Primary | 21 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 16 | Octagam10% | Primary | 37 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 16 | Placebo | At least moderate improvement | 11 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 16 | Octagam10% | At least moderate improvement | 32 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 16 | Placebo | At least major improvement | 4 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 16 | Octagam10% | At least major improvement | 15 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 40 | Placebo | At least minimal improvement | 32 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 40 | Octagam10% | At least minimal improvement | 32 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 40 | Placebo | At least moderate improvement | 28 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 40 | Octagam10% | At least moderate improvement | 26 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 40 | Placebo | At least major improvement | 14 | Participants | |
| Proportion of TIS Responders by Improvement Category at Week 40 | Octagam10% | At least major improvement | 17 | Participants | |
| Mean Change From Baseline (Week 0) to End of First Period (Week 16) in the Modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Placebo | Total Activity Score | -1.16 | Standard Deviation 7.000 | units on a scale |
| Mean Change From Baseline (Week 0) to End of First Period (Week 16) in the Modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Octagam10% | Total Activity Score | -9.36 | Standard Deviation 10.542 | units on a scale |
| Mean Change From Baseline (Week 0) to End of First Period (Week 16) in the Modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Placebo | Total Damage Score | -0.02 | Standard Deviation 0.771 | units on a scale |
| Mean Change From Baseline (Week 0) to End of First Period (Week 16) in the Modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Octagam10% | Total Damage Score | -0.67 | Standard Deviation 1.871 | units on a scale |
| Mean Change From End of First Period (Week 16) to End of Extension Period (Week 40) in the Modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Placebo | Total Activity Score | -8.52 | Standard Deviation 11.344 | units on a scale |
| Mean Change From End of First Period (Week 16) to End of Extension Period (Week 40) in the Modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Octagam10% | Total Activity Score | -1.79 | Standard Deviation 4.169 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02728752/results